[Skip to Content]
[Skip to Content Landing]
Views 7,057
Citations 0
Editorial
April 10, 2018

Time to Converge FDA Decisions and Evidence Syntheses for Long-Acting Muscarinic Antagonists and SMART in Guidelines for the Treatment of Asthma

Author Affiliations
  • 1Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois, Chicago
  • 2Health Services Research and Development Service, Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
  • 3Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle
JAMA. 2018;319(14):1441-1443. doi:10.1001/jama.2018.2029

Asthma is a chronic pulmonary disorder characterized by variable levels of dyspnea, chest tightness, wheezing, and cough that can disrupt sleep, work, and school. Asthma is a major public health problem that affects 235 million people worldwide, including 25 million people in the United States alone. Uncontrolled asthma contributes to 10.5 million days of missed school, 14.2 million days of missed work, and more than 3600 premature deaths in the United States each year.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview
×